Skip to content
Evigrade
ModerateReversible P2Y12 receptor inhibitor×Vitamin K antagonist anticoagulants

Updated · Methodology

Mechanism

Warfarin blocks the vitamin K-dependent formation of active clotting factors II, VII, IX and X in the liver (warfarin summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS). Ticagrelor reversibly blocks the platelet P2Y12 receptor and so prevents platelet activation and aggregation (ticagrelor SmPC, European Medicines Agency, EMA). The US warfarin label lists antiplatelet agents among drugs that increase the risk of bleeding (US Food and Drug Administration, FDA). Ticagrelor does not inhibit CYP2C9, the enzyme that metabolises warfarin: plasma levels did not change with tolbutamide, so an effect on warfarin metabolism is unlikely (ticagrelor SmPC, EMA).

Symptoms

The risk of bleeding from any tissue or organ rises, including fatal bleeding. Signs and severity depend on the site and extent of bleeding (warfarin summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS). Bleeding complications may present as paralysis, numbness, headache, chest, abdominal or muscle pain, dizziness, shortness of breath, difficulty breathing or swallowing, unexplained swelling, weakness, low blood pressure or unexplained shock (AEMPS). Bleeding does not always match the international normalised ratio (INR) (AEMPS). The most frequently reported adverse reactions with ticagrelor are bleeding and shortness of breath (ticagrelor SmPC, European Medicines Agency, EMA).

Management

There is no contraindication for this pair. If the combination is clinically indicated, use ticagrelor with caution in patients who take oral anticoagulants within 24 hours of a ticagrelor dose. In patients at known high risk of bleeding, weigh the benefit of ticagrelor against that risk (ticagrelor summary of product characteristics, SmPC, European Medicines Agency, EMA). Whenever another drug is added to or withdrawn from warfarin, monitor coagulation strictly, and take extra international normalised ratio (INR) measurements when other medicines are started, stopped or taken irregularly (warfarin summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US warfarin label, closely monitor patients who take antiplatelet agents with warfarin (warfarin prescribing information, US Food and Drug Administration, FDA). Give ticagrelor with a low maintenance dose of acetylsalicylic acid, 75–150 mg a day, unless it is contraindicated (ticagrelor SmPC, EMA). Before elective surgery, if an antiplatelet effect is not needed, stop ticagrelor 5 days in advance (EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ticagrelor

Other interactions with Warfarin